Hilde Steineger, CEO
Hilde H. Steineger joined Staten Biotech in December 2017. Prior to joining Staten Biotech, Hilde served as Head of Strategic Innovation Management in Nutrition and Health Division (EN), BASF and Head of Global Omega-3 innovation Management including; R&D, Medical affairs and Business Development. She has also served as Vice President, Head of Investor Relations for Pronova BioPharma, Senior Associate at Neomed Management and as a Senior sell-side Analyst at Nordea Securities. She has for the last 15 years served as member of board of directors in a number of listed biotech companies, in Norway and in US. Dr. Hilde Steineger has broad scientific knowledge with a PhD in medical biochemistry from the University of Oslo in 2000 and an MSc in molecular biology/biotechnology from 1992.
Paul da Silva Jardine, Co-founder and CSO
Paul Da Silva Jardine is co-founder and CSO at Staten. He brings extensive know-how in drug development in the cardiovascular field. He is a former VP at Pfizer R & D who spent more than 24 years at Pfizer managing project teams delivering over 50 clinical candidates in cardiovascular, obesity, diabetes and osteoporosis. He discovered and led early clinical team for SERM, Lasofoxifene approved in Europe. Most recently, he was VP or Research in the Cardiovascular and Metabolic Diseases (CVMED) Research Unit at Pfizer responsible for projects from target identification to end of Phase 2.
Peter Tjeerdsma, Director of CMC
Peter Tjeerdsma is director of CMC at Staten. He has obtained his MSc in bioprocess technology from Wageningen University and his Professional Doctorate in Engineering (PDEng) in bioprocess design from Delft University of Technology. Peter has 15 years of project management experience in the pharmaceutical industry of which 7 years as CMC leader in Janssen (J&J), accountable for process and analytical development and manufacturing of various compounds, including monoclonal antibodies, complex proteins, and viral vaccine products. During his career Peter has successfully led various CMC-teams from pre-phase 1 to post phase 3, performed several regulatory submissions, including INDs, IMPDs, Scientific Advice, Type C and a WHO EUAL. As director of CMC at Staten Biotechnology, he is using all his prior knowledge, experience, and skills, and learning new ones to build Staten’s CMC capabilities and to help Staten achieve it’s objectives.
John Kastelein, CMO
John Kastelein is professor of medicine, chairman of the department of vascular medicine, and holds the Strategic Chair of Genetics at Cardiovascular Disease at the Academic Medical Center of the University of Amsterdam. Dr. Kastelein is a member of the Steering Committees of Lipid lowering and cardiovascular intervention trials. His main interest is in the development of novel therapies for Cardiovascular Diseases and the genetic basis or dyslipidemia. Dr. Kastelein was awarded a doctorate in Medicine (with Honors) from the University of Amsterdam, trained in internal medicine at the Academic Medical Center of the University of Amsterdam, and trained in lipidology and molecular biology at the University of British Columbia in Vancouver. He is president of the Dutch Atherosclerosis Society and the National Scientific Committee on Familial Hypercholesterolemia and also a Fellow of the European Society of Cardiology (FESC). In 2010, awarded the prestigious Dutch Heart Association prize of EUR 1 million and in 2011 the ZonMw Pearl for his research in the field of gene therapy.
Vincent van Houten, CFO
As of January 2017, Vincent is acting Chief Financial Officer for Staten. Vincent holds a Master's degree from the University of Amsterdam, has a Finance and Accounting background, and has experience in corporate and fiscal (re)structuring. Vincent is primarily the Chief Financial Officer for Forbion and in that capacity, he is responsible for the overall financial and fiscal affairs of Forbion and its affiliates. As part of the Forbion Investment Team Vincent also has portfolio related financial topics and as such Vincent is seconded to Staten as acting CFO. Previously he has had a similar assignment for Forbion as acting Chief Financial Officer for Dezima Pharma BV, and played and active role in the acquisition of Dezima by Amgen in 2015.
Arnoud Dijkstra, Chief Business Officer
Arnoud joined Staten as acting-CBO in April 2017. After having spent 14 years in the Basel pharma industry, with his career ranging from research management in antibacterial R&D at Hoffmann-La Roche to business development and investor relations at Actelion, Arnoud moved back to the Netherlands to join the Forbion portfolio antibody company PanGenetics as Chief Business Officer until it was sold to Abbott. He then was CBO of the hemostasis company Profibrix, which was acquired by The Medicines Company. He currently holds interim management positions in and provides consultancy services to several life science companies and is a Venture Advisor at BioGeneration Ventures.
Patrick Round, Medical Director
Patrick Round joined Staten in 2015. He previously was CMO and CEO of Xention Limited and was responsible for all the clinical development work for Dezima prior to its acquisition by Amgen. Before Xention he was Senior Vice President of Development at Cambridge Antibody Technology when it was acquired by Astra Zeneca. He also served as Director of Development at Celltech, Director of Clinical Development at Glaxo Wellcome and started his pharma career as a medical adviser at Novo Nordisk in 1991 in the UK and later in Denmark. He received his medical degree from Charing Cross Hospital Medical School in London in 1982, became a Fellow of the Royal College of Anaesthetists in 1990 and a Fellow of the Faculty of Pharmaceutical Medicine in 2005. Patrick is a Venture Partner at Forbion.